Gilead Sciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Gilead Sciences, Inc.
Allogene May Have Cracked The Off-The-Shelf CAR-T Problem
Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.
ASCO 2023 – Trop2 Could Validate Merck’s Savvy Deal With Kelun
In Trop2 Merck & Co. might have got itself an ADC at least as good as Gilead and Astra/Daiichi’s leaders, for a fraction of the price.
From Inflection To Insight: Vertex And Merck’s Dueling HCV Drugs
Welcome to Inflection to Insight, a new series taking a closer look at notable chapters in biopharma history, gleaning learnings to inform current business strategy. This inaugural instalment looks at the rapid rise and fall of two competing drugs for hepatitis C virus, Vertex’s Incivek and Merck & Co’s Victrelis.
AbbVie's Rinvoq Succeeds Against The Odds In Phase II Lupus Trial
Despite a troubled history of JAK inhibitors in lupus trials, AbbVie’s Rinvoq has hit the mark in a mid-stage study of the condition, shifting focus to a pivotal program that could expand the blockbuster drug’s reach.
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Arresto Biosciences, Inc.
- Asegua Therapeutics, LLC
- Calistoga Pharmaceuticals, Inc.
- Cell Design Labs, Inc.
- CGI Pharmaceuticals, Inc.
- CV Therapeutics, Inc.
- Cytopia Limited
- Eximias Pharmaceutical Corporation
- Immunomedics, Inc.
- Kite Pharma EU
- Kite Pharma, Inc.
- MYR GmbH
- Nimbus Apollo, Inc.
- Nexstar Pharmaceuticals
- Oligogen, Inc.
- Pharmasset, Inc.
- T-Cell Factory B.V. (TCF)
- Triangle Pharmaceuticals
- XinThera, Inc.
- YM BioSciences Inc. (YMI)
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.